Amber R. Prebble
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amber R. Prebble has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Del Leary
Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA
3 shared publications - Mary-Keara Boss
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins Colorado USA
3 shared publications Del Leary
Environmental and Radiological Health Sciences Colorado State University Fort Collins USA
2 shared publications- Tiffany Wormhoudt Martin
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins Colorado USA
2 shared publications - Bailey Latka
Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
1 shared publication - Bernard Séguin
Flint Animal Cancer Center Colorado State University Fort Collins Colorado USA
1 shared publication
Latest Publications
- 30 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 805, 153352
Biological effectiveness of superficial X-ray in mammalian cells through precise dosimetry and Monte Carlo simulations
- 30 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 805, 153352
Biological effectiveness of superficial X-ray in mammalian cells through precise dosimetry and Monte Carlo simulations
- Open Access
- 5 August 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (8) , 735
The Effect of Cannabidiol in Conjunction with Radiation Therapy on Canine Glioma Cell Line Transplanted in Immunodeficient Mice
Glioma is a type of neoplasia that spontaneously arises from the glial cells of the brain in humans and dogs, and its prognosis is grave. Current treatment options for glioma include surgery, radiation therapy, chemotherapy, or symptomatic treatment. Evidence has shown that cannabidiol (CBD) may have anticancer, anti-angiogenic, and anti-inflammatory properties in both in vitro and in vivo studies. In this in vivo murine experiment, the canine glioma cell line J3TBG was injected into the frontoparietal cortex of immunodeficient mice using xenogeneic tissue transplantation. A total of 20 mice were randomly assigned to one of four treatment groups—Control group (C), CBD group (CBD), Radiation Therapy group (RT), and CBD plus Radiation Therapy group (CBD + RT). After transplantation of J3TBG, a single fraction of 5.5 Gy RT was administered to the RT and CBD + RT groups, and CBD was administered daily to the CBD and CBD + RT groups. Necropsies were performed to collect blood and brain tissue. Although there was not a statistically significant difference, the survival time among mice were longer in the CBD + RT group than the RT group. These results indicate that CBD may be used as an adjunctive therapy to enhance RT treatment. Larger cohort studies are required to substantiate the hypothesis.
- 5 August 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (8) , 735
Open AccessThe Effect of Cannabidiol in Conjunction with Radiation Therapy on Canine Glioma Cell Line Transplanted in Immunodeficient Mice
Glioma is a type of neoplasia that spontaneously arises from the glial cells of the brain in humans and dogs, and its prognosis is grave. Current treatment options for glioma include surgery, radiation therapy, chemotherapy, or symptomatic treatment. Evidence has shown that cannabidiol (CBD) may have anticancer, anti-angiogenic, and anti-inflammatory properties in both in vitro and in vivo studies. In this in vivo murine experiment, the canine glioma cell line J3TBG was injected into the frontoparietal cortex of immunodeficient mice using xenogeneic tissue transplantation. A total of 20 mice were randomly assigned to one of four treatment groups—Control group (C), CBD group (CBD), Radiation Therapy group (RT), and CBD plus Radiation Therapy group (CBD + RT). After transplantation of J3TBG, a single fraction of 5.5 Gy RT was administered to the RT and CBD + RT groups, and CBD was administered daily to the CBD and CBD + RT groups. Necropsies were performed to collect blood and brain tissue. Although there was not a statistically significant difference, the survival time among mice were longer in the CBD + RT group than the RT group. These results indicate that CBD may be used as an adjunctive therapy to enhance RT treatment. Larger cohort studies are required to substantiate the hypothesis.
- Open Access
- 4 March 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (6) , e70062
Monte Carlo modeling of radiation dose from radiation therapy with superficial x‐rays
Introduction: Superficial x‐rays (50–100 kVp) are used for treating non‐melanoma skin cancer and intraoperative radiation therapy (IORT). At these energies, the photoelectric effect significantly increases absorbed dose to bone compared to soft tissue.Methods: We used EGSnrc MC simulations to investigate bone dose enhancement during radiotherapy with the Sensus SRT‐100 machine. Simulated beams were validated against laboratory measurements and compared to a commercial treatment planning system (SmART‐ATP). Transmission simulations indirectly predicted bone dosage. Simulated beams were utilized as a mock treatment plan from a human cone‐beam computed tomography (CBCT) image.Results: EGSnrc accurately modeled the Sensus SRT‐100 beams (100, 70, and 50 kVp) with a root mean square error (RMSE) of percentage depth dose ratios between Monte Carlo predictions and lab measurements of 1.66, 0.47, and 0.99, respectively. PDDs from simulations of a water phantom with bone slabs showed peak doses at water–bone interfaces relative to surface doses. At 0.3 cm depth bone slab, doses reached 410%, 490%, and 510% for 50, 70, and 100 kVp, respectively. At 1.5 cm depth, doses were 140%, 215%, and 270%. At 2.5 cm depth, peak doses were 74%, 130%, and 170% for 50, 70, and 100 kVp, respectively. A simulated treatment plan (4 Gy surface dose) using a CBCT of a human head predicted the dose to the skull to be around 20, 19, and 15 Gy for the 100, 70, and 50 kVp beams, respectively.Conclusions: The study demonstrated EGSnrc's efficiency in conjunction with SmART‐ATP for treatment planning. MC simulations effectively quantified bone dose enhancement during superficial x‐ray radiotherapy, highlighting its importance in treatment planning and dose calculations. Clinicians should consider measuring bone depth prior to treatment to avoid excessive bone dose.
- 4 March 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (6) , e70062
Open AccessMonte Carlo modeling of radiation dose from radiation therapy with superficial x‐rays
Introduction: Superficial x‐rays (50–100 kVp) are used for treating non‐melanoma skin cancer and intraoperative radiation therapy (IORT). At these energies, the photoelectric effect significantly increases absorbed dose to bone compared to soft tissue.Methods: We used EGSnrc MC simulations to investigate bone dose enhancement during radiotherapy with the Sensus SRT‐100 machine. Simulated beams were validated against laboratory measurements and compared to a commercial treatment planning system (SmART‐ATP). Transmission simulations indirectly predicted bone dosage. Simulated beams were utilized as a mock treatment plan from a human cone‐beam computed tomography (CBCT) image.Results: EGSnrc accurately modeled the Sensus SRT‐100 beams (100, 70, and 50 kVp) with a root mean square error (RMSE) of percentage depth dose ratios between Monte Carlo predictions and lab measurements of 1.66, 0.47, and 0.99, respectively. PDDs from simulations of a water phantom with bone slabs showed peak doses at water–bone interfaces relative to surface doses. At 0.3 cm depth bone slab, doses reached 410%, 490%, and 510% for 50, 70, and 100 kVp, respectively. At 1.5 cm depth, doses were 140%, 215%, and 270%. At 2.5 cm depth, peak doses were 74%, 130%, and 170% for 50, 70, and 100 kVp, respectively. A simulated treatment plan (4 Gy surface dose) using a CBCT of a human head predicted the dose to the skull to be around 20, 19, and 15 Gy for the 100, 70, and 50 kVp beams, respectively.Conclusions: The study demonstrated EGSnrc's efficiency in conjunction with SmART‐ATP for treatment planning. MC simulations effectively quantified bone dose enhancement during superficial x‐ray radiotherapy, highlighting its importance in treatment planning and dose calculations. Clinicians should consider measuring bone depth prior to treatment to avoid excessive bone dose.
- Open Access
- 2 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1838
Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model
Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.
- 2 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1838
Open AccessInvestigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model
Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.
- 26 July 2021
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 20 (1) , 142-153
Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate
Receptor tyrosine kinase inhibitors (TKIs) are used to treat human and canine cancers and may be combined with radiation therapy (RT) to enhance tumor control due their anticancer and antiangiogenic effects; however, recent case reports have emerged describing incidences of gastrointestinal toxicity when antiangiogenic therapies are combined with hypofractionated radiotherapy in human cancer patients. We evaluated the incidence of gastrointestinal (GI) toxicity in dogs receiving concurrent hypofractionated abdominal RT and the TKI toceranib (TOC) compared to those receiving abdominal RT alone, TOC alone, or concurrent non‐abdominal RT and TOC. Medical records of canine cancer patients were retrospectively reviewed and identified dogs were included in the following treatment categories: dogs which received RT to a portion of the abdomen and concurrent TOC (n = 19), abdominal RT alone (n‐29), TOC alone (n = 20), or non‐abdominal RT plus TOC (n = 9). Toxicities were graded using the Veterinary Cooperative Oncology Group ‐ Common Terminology Criteria for Adverse Events criteria and compared to published data on TOC‐associated GI toxicity. Patients receiving TOC while undergoing abdominal RT had significantly increased rates of any grade of diarrhea (p = 0.002), hyporexia (p = 0.0045), and vomiting (p = 0.003), as well as severe hyporexia (p = 0.003) when compared across the treatment groups. This retrospective study reveals significantly increased incidences of GI toxicity when abdominal RT is combined with TOC in canine patients. These findings are in‐line with the clinical concerns reported for increased normal tissue toxicity in human patients when antiangiogenics are combined with RT.
- 26 July 2021
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 20 (1) , 142-153
Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate
Receptor tyrosine kinase inhibitors (TKIs) are used to treat human and canine cancers and may be combined with radiation therapy (RT) to enhance tumor control due their anticancer and antiangiogenic effects; however, recent case reports have emerged describing incidences of gastrointestinal toxicity when antiangiogenic therapies are combined with hypofractionated radiotherapy in human cancer patients. We evaluated the incidence of gastrointestinal (GI) toxicity in dogs receiving concurrent hypofractionated abdominal RT and the TKI toceranib (TOC) compared to those receiving abdominal RT alone, TOC alone, or concurrent non‐abdominal RT and TOC. Medical records of canine cancer patients were retrospectively reviewed and identified dogs were included in the following treatment categories: dogs which received RT to a portion of the abdomen and concurrent TOC (n = 19), abdominal RT alone (n‐29), TOC alone (n = 20), or non‐abdominal RT plus TOC (n = 9). Toxicities were graded using the Veterinary Cooperative Oncology Group ‐ Common Terminology Criteria for Adverse Events criteria and compared to published data on TOC‐associated GI toxicity. Patients receiving TOC while undergoing abdominal RT had significantly increased rates of any grade of diarrhea (p = 0.002), hyporexia (p = 0.0045), and vomiting (p = 0.003), as well as severe hyporexia (p = 0.003) when compared across the treatment groups. This retrospective study reveals significantly increased incidences of GI toxicity when abdominal RT is combined with TOC in canine patients. These findings are in‐line with the clinical concerns reported for increased normal tissue toxicity in human patients when antiangiogenics are combined with RT.
- 9 June 2020
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 18 (4) , 843-853
Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma
Thyroid carcinoma develops spontaneously in dogs, with only 25% to 50% of cases amenable to surgery at diagnosis. Local control for unresectable tumours can be provided with external beam radiotherapy. The aim of this retrospective study is to describe the safety and efficacy of stereotactic body radiation therapy (SBRT) for treatment of canine thyroid carcinoma. Twenty‐three dogs met inclusion criteria; median tumour volume before SBRT was 129.9 cm3(range, 2.7‐452.8 cm3). Sixteen patients (70%) had unresectable tumours. Pulmonary metastasis was present or suspected in 10 patients (44%) before SBRT. Patients were prescribed 15 to 40 Gy to targeted tumour volume in one to five fractions. Twenty patients evaluated had overall response rate of 70% (complete response, n = 4; partial response, n = 10). Thirteen out of sixteen (81%) symptomatic patients had clinical improvement within a median time of 16 days (range, 2‐79 days). Median progression free survival (MPFS) was 315 days. Median survival time (MST) was 362 days. Nine patients (39%) had grade 1 acute radiation toxicity. Three patients had grade 1 late radiation toxicity (two leukotrichia and one [4%] with intermittent cough). Responders had significantly longer MPFS (362 vs 90 days; HR 4.3; 95% CI 1.4‐13.5;P= .013) and MST (455 vs 90 days; HR 2.9; 95% CI 1‐8.4;P= .053). Presenting with metastasis was not a significant negative prognostic factor (MST 347 vs 348 days without metastasis;P= .352). SBRT is a safe and effective treatment modality for non‐resectable canine thyroid carcinoma.
- 9 June 2020
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 18 (4) , 843-853
Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma
Thyroid carcinoma develops spontaneously in dogs, with only 25% to 50% of cases amenable to surgery at diagnosis. Local control for unresectable tumours can be provided with external beam radiotherapy. The aim of this retrospective study is to describe the safety and efficacy of stereotactic body radiation therapy (SBRT) for treatment of canine thyroid carcinoma. Twenty‐three dogs met inclusion criteria; median tumour volume before SBRT was 129.9 cm3(range, 2.7‐452.8 cm3). Sixteen patients (70%) had unresectable tumours. Pulmonary metastasis was present or suspected in 10 patients (44%) before SBRT. Patients were prescribed 15 to 40 Gy to targeted tumour volume in one to five fractions. Twenty patients evaluated had overall response rate of 70% (complete response, n = 4; partial response, n = 10). Thirteen out of sixteen (81%) symptomatic patients had clinical improvement within a median time of 16 days (range, 2‐79 days). Median progression free survival (MPFS) was 315 days. Median survival time (MST) was 362 days. Nine patients (39%) had grade 1 acute radiation toxicity. Three patients had grade 1 late radiation toxicity (two leukotrichia and one [4%] with intermittent cough). Responders had significantly longer MPFS (362 vs 90 days; HR 4.3; 95% CI 1.4‐13.5;P= .013) and MST (455 vs 90 days; HR 2.9; 95% CI 1‐8.4;P= .053). Presenting with metastasis was not a significant negative prognostic factor (MST 347 vs 348 days without metastasis;P= .352). SBRT is a safe and effective treatment modality for non‐resectable canine thyroid carcinoma.